Oxford University to test COVID-19 vaccine safety in Kids
This test will assess whether children 6–17 years of age and young adults develop a good immune response with the ChAdOx1 nCoV-19 vaccine.
The University of Oxford has launched the first study during this month to assess the safety and immune responses of its Kovid-19 vaccine in previously vaccinated children and young adults.This test will assess whether children 6–17 years of age and young adults develop a good immune response with the ChAdOx1 nCoV-19 vaccine.
"While most children are relatively unaffected by coronovirus and are unlikely to be unwell with infection, it is important to establish the vaccine's safety and immune response in children and young people as some children may benefit from vaccination," Andrew Murd, Professor , And the lead investigator on the Oxford vaccine trial, said in a statement.
"These new trials will expand our understanding of the control of SARS-COV2 to younger age groups."
The study builds on previous vaccine trials that have shown that it is safe, produces strong immune system responses and has high efficacy in adults. This new trial will involve 300 volunteers in a single-blind, randomized phase II trial. The University of Oxford said on Friday that up to 240 of these volunteers receive the ChAdOx1 nCoV-19 vaccine.
The remainder will receive a control meningitis vaccine, which has been shown to be safe in children, but is expected to cause similar reactions, such as a sore throat."The covid-19 epidemic has profoundly negative effects on the education, social development, and emotional well-being of children and adolescents beyond illness and rare critical illnesses," said Rin Song, pediatrician and clinician-scientist, Oxford Vaccine Group.
"It is therefore important to collect data on the safety and immune response of our coronavirus vaccines in these age groups, so that they may potentially benefit from involvement in vaccination programs in the near future."The trial is funded by the UK's National Institutes for Health Research (NIHR) and drugmaker AstraZeneca.